The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy

Behavioural Brain Research

Volumn 291, Issue , 2015, Pages 80-88

  Fardell, Joanna E ^a   Vardy, Janette ^b   Monds, Lauren A ^b   Johnston, Ian N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemotherapy; Cognition; Mechanical allodynia; Oxaliplatin; Peripheral neuropathy; Rat

Indexed keywords

OXALIPLATIN; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; MALE; MECHANICAL SENSITIVITY; MECHANICAL STIMULATION; MEMORY; NONHUMAN; NOVEL LOCATION RECOGNITION; NOVEL OBJECT RECOGNITION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; RECOGNITION; RECOGNITION MEMORY; WISTAR RAT; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HYPERALGESIA; PATHOPHYSIOLOGY; TIME FACTOR; TOUCH;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; MALE; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); TIME FACTORS; TOUCH;

EID: 84930194747     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.04.038     Document Type: Article

References (76)

1. Janelsins M.C., Kohli S., Mohile S.G., Usuki K., Ahles T.A., Morrow G.R. An update on cancer- and chemotherapy-related cognitive dysfunction: Current status. Semin Oncol 2011, 38(3):431-438.
2. Shilling V., Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007, 11(1):6-15.
3. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002 Jan 15, 20(2):485-493.
4. de Ruiter M.B., Reneman L., Boogerd W., Veltman D.J., van Dam F.S., Nederveen A.J., et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2010, 32:1206-1219.
5. Silverman D.H., Dy C.J., Castellon S.A., Lai J., Pio B.S., Abraham L., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007 Jul, 103(3):303-311.
6. Hedayati E., Alinaghizadeh H., Schedin A., Nyman H., Albertsson M. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs 2011 Sep 9, 16:315-322.
7. Ahles T.A., Saykin A.J., McDonald B.C., Li Y., Furstenberg C.T., Hanscom B.S., et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010 Oct 10, 28(29):4434-4440.
8. Schagen S.B., Muller M.J., Boogerd W., Mellenbergh G.J., van Dam F.S. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006, 98(23):1742-1745.
9. Gandal M.J., Ehrlichman R.S., Rudnick N.D., Siegel S.J. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008 Nov 11, 157(1):95-104.
10. Konat G.W., Kraszpulski M., James I., Zhang H.T., Abraham J. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 2008 Sep, 23(3):325-333.
11. MacLeod J.E., DeLeo J.A., Hickey W.F., Ahles T.A., Saykin A.J., Ucci D.J.B. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007, 181(1):168-172.
12. Mustafa S., Walker A., Bennett G., Wigmore P.M. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurosci 2008 Jul, 28(2):323-330.
13. Seigers R., Schagen S.B., Beerling W., Boogerd W., Van Tellingen O., Van Dam F., et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008, 186(2):168-175.
14. Seigers R., Schagen S.B., Coppens C.M., van der Most P.J., van Dam F.S.A.M., Koolhaas J.M., et al. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res 2009, 201(2):279-284.
15. Winocur G., Vardy J., Binns M.A., Kerr L., Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006 Sep, 85(1):66-75.
16. Li C.Q., Liu D., Huang L., Wang H., Zhang J.Y., Luo X.G. Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats. Brain Res Bull 2008 Aug 25, 77(5):237-240.
17. Mondie C.M., Vandergrift K.A., Wilson C.L., Gulinello M.E., Weber E.T. The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav Brain Res 2010, 209:66-72.
18. Fremouw T., Fessler C.L., Ferguson R.J., Burguete Y. Preserved learning and memory in mice following chemotherapy: 5-Fluorouracil and doxorubicin single agent treatment, doxorubicin-cyclophosphamide combination treatment. Behav Brain Res 2012, 226(1):154-162.
19. Lee G.D., Longo D.L., Wang Y., Rifkind J.M., Abdul-Raman L., Mamczarz J.A., et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006, 12(1):198-205.
20. Long J.M., Lee G.D., Kelley-Bell B., Spangler E.L., Perez E.J., Longo D.L., et al. Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav 2011, 100(1):205-211.
21. Schagen S.B., Boogerd W., Muller M.J., Huinink W.T., Moonen L., Meinhardt W., et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008, 47(1):63-70.
22. Skaali T., Fossa S.D., Dahl A.A. A prospective study of cognitive complaints in patients with testicular cancer. Clin Genitourin Cancer 2011, 9(1):6-13.
23. Skaali T., Fossa S.D., Andersson S., Cvancarova M., Langberg C.W., Lehne G., et al. Self-reported cognitive problems in testicular cancer patients: Relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res 2011, 70(5):403-410.
24. Song T.Y., Chen C.L., Liao J.W., Ou H.C., Tsai M.S. Ergothioneine protects against neuronal injury induced by cisplatin both in vitro and in vivo. Food Chem Toxicol 2010, 48(12):3492-3499.
25. Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5(7):22.
26. Siu L.L., Moore R.G. Pharmacology of anticancer drugs. The Basic Science of Pncology 2004, 322-348. McGraw-Hill, New York. 4th ed. I. Tannock, R. Hill, R. Bristow, L. Harrington (Eds.).
27. Alcindor T., Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011, 18(1):18-25.
28. Verstappen C.C., Heimans J.J., Hoekman K., Postma T.J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003, 63(15):1549-1563.
29. Park S.B., Lin C.S., Krishnan A.V., Goldstein D., Friedlander M.L., Kiernan M.C. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011 Apr 8, 16(5):708-716.
30. Holmes J., Stanko J., Varchenko M., Ding H., Madden V.J., Bagnell C.R., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 1998, 46(2):342-351.
31. Sharpe M.J., Fardell J.E., Vardy J., Johnston I.N. The chemotherapy agent oxaliplatin impairs the renewal of fear to an extinguished conditioned stimulus in rats. Behav Brain Res 2011, 227(1):295-299.
32. Fardell J.E., Vardy J., Shah J.D., Johnston I.N. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology 2012, 220(1):183-193.
33. Fardell J.E., Vardy J., Johnston I.N. The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sci 2013, 93(17):596-604.
34. Lyons L., Elbeltagy M., Bennett G., Wigmore P. The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat. PLoS One 2011, 6(6):e21445.
35. Lyons L., Elbeltagy M., Umka J., Markwick R., Startin C., Bennett G., et al. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology (Berl) 2011, 215(1):105-115.
36. Dix S.L., Aggleton J.P. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav Brain Res 1999, 99(2):191-200.
37. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988 Nov 1, 31(1):47-59.
38. Johnston I.N., Milligan E.D., Wieseler-Frank J., Frank M.G., Zapata V., Campisi J., et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004, 24(33):7353-7365.
39. Gaskin S., Tremblay A., Mumby D.G. Retrograde and anterograde object recognition in rats with hippocampal lesions. Hippocampus 2003, 13(8):962-969.
40. Li Y., Vijayanathan V., Gulinello M.E., Cole P.D. Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. Pharmacol Biochem Behav 2010, 94(3):454-463.
41. Foley J.J., Raffa R.B., Walker E.A. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology 2008, 199(4):527-538.
42. Liedke P.E.R., Reolon G.K., Kilpp B., Brunetto A.L., Roesler R., Schwartsmann G. Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav 2009, 94(2):239-243.
43. Van Dam F.S.A.M., Schagen S.B., Muller M.J., Boogerd W., Wall E V.D., Droogleever Fortuyn M.E., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90(3):210-218.
44. Li Y., Vijayanathan V., Gulinello M., Cole P.D. Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav 2010, 95(4):428-433.
45. Vijayanathan V., Gulinello M., Ali N., Cole P.D. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav Brain Res 2011, 225(2):491-497.
46. Ghirardi O., Lo Giudice P., Pisano C., Vertechy M., Bellucci A., Vesci L., et al. Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005, 25(4):2681-2687.
47. Ling B., Coudore-Civiale M.A., Balayssac D., Eschalier A., Coudore F., Authier N. Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology 2007, 234(3):176-184.
48. Baek K.K., Lee J., Park S.H., Park J.O., Park Y.S., Lim H.Y., et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010, 42(4):185-190.
49. Burakgazi A.Z., Messersmith W., Vaidya D., Hauer P., Hoke A., Polydefkis M. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011, 77(10):980-986.
50. Cavaletti G., Petruccioli M.G., Marmiroli P., Rigolio R., Galbiati S., Zoia C., et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res 2002, 22(6C):4199-4204.
51. Cavaletti G., Tredici G., Petruccioli M.G., Donde E., Tredici P., Marmiroli P., et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001, 37(18):2457-2463.
52. Park S.B., Krishnan A.V., Lin C.S., Goldstein D., Friedlander M., Kiernan M.C. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008, 15(29):3081-3094.
53. Pietrangeli A., Leandri M., Terzoli E., Jandolo B., Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006, 56(1):13-16.
54. Xiao W.H., Zheng H., Bennett G.J. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012, 203:194-206.
55. Brouwers E.E., Huitema A.D., Beijnen J.H., Schellens J.H. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008, 8:7.
56. Sprauten M., Darrah T.H., Peterson D.R., Campbell M.E., Hannigan R.E., Cvancarova M., et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol 2012, 30(3):300-307.
57. Gregg R.W., Molepo J.M., Monpetit V.J., Mikael N.Z., Redmond D., Gadia M., et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992, 10(5):795-803.
58. Ta L.E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006, 27(6):992-1002.
59. Brouwers E.E.M., Huitema A.D.R., Boogerd W., Beijnen J.H., Schellens J.H.M. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009, 48(6):832-841.
60. Kopetz S., Lesslie D.P., Dallas N.A., Park S.I., Johnson M., Parikh N.U., et al. Synergistic activity of the Src family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009, 69(9):3842-3849.
61. Lim S.C., Choi J.E., Kang H.S., Han S.I. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer 2010, 126(7):1582-1595.
62. Joseph E.K., Chen X., Bogen O., Levine J.D. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008, 9(5):463-472.
63. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008, 34(4):368-377.
64. Jacobs S., McCully C.L., Murphy R.F., Bacher J., Balis F.M., Fox E. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 2010, 65(5):817-824.
65. Joshi G., Sultana R., Tangpong J., Cole M.P., St Clair D.K., Vore M., et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 2005, 39(11):1147-1154.
66. Joshi G., Hardas S., Sultana R., St Clair D.K., Vore M., Butterfield D.A. Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res 2007, 85(3):497-503.
67. Patel R.S., Rachamalla M., Chary N.R., Shera F.Y., Tikoo K., Jena G. Cytarabine induced cerebellar neuronal damage in juvenile rat: Correlating neurobehavioral performance with cellular and genetic alterations. Toxicology 2011, 293:41-52.
68. Helal G.K., Aleisa A.M., Helal O.K., Al-Rejaie S.S., Al-Yahya A.A., Al-Majed A.A., et al. Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats. Oxid Med Cell Longev 2009, 2(1):26-35.
69. Koros C., Papalexi E., Anastasopoulos D., Kittas C., Kitraki E. Effects of AraC treatment on motor coordination and cerebellar cytoarchitecture in the adult rat. A possible protective role of NAC. Neuro Toxicol 2007, 28(1):83-92.
70. Norcini M., Vivoli E., Galeotti N., Bianchi E., Bartolini A., Ghelardini C. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain 2009, 146(1-2):141-147.
71. Di Cristo G., Berardi N., Cancedda L., Pizzorusso T., Putignano E., Ratto G.M., et al. Requirement of ERK activation for visual cortical plasticity. Science 2001, 292(5525):2337-2340.
72. Kyosseva S.V. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 2004, 59:201-220.
73. Zhang G.R., Wang X., Kong L., Lu X.G., Lee B., Liu M., et al. Genetic enhancement of visual learning by activation of protein kinase C pathways in small groups of rat cortical neurons. J Neurosci 2005, 25(37):8468-8481.
74. Zhang G., Liu M., Cao H., Kong L., Wang X., O'ÄôBrien J.A., et al. Improved spatial learning in aged rats by genetic activation of protein kinase C in small groups of hippocampal neurons. Hippocampus 2009, 19(5):413-423.
75. Winters B.D., Saksida L.M., Bussey T.J. Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 2008, 32(5):1055-1070.
76. Vardy J., Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 2007, 63(3):183-202.